Updated Jan 09, 2021 | 13:30 IST
Bharat Biotech says its intranasal vaccine candidate against COVID-19 has demonstrated unprecedented levels of protection in mice studies. What you need to know about Bharat Biotech’s intranasal COVID-19 vaccine BBV154 | Photo Credit: iStock Images
Key Highlights
Bharat Biotech to start phase 1 trials of its intranasal vaccine for COVID-19 in February-March
The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa
The company owns the right to distribute the intranasal vaccine for COVID-19 in all markets except USA, Japan and Europe
Hyderabad: Bharat Biotech on Friday announced that it will begin the phase1 clinical trials of its new intranasal vaccine for the novel coronavirus (SARS-CoV-2) in February-March this year. The development came days after the Hyderabad-based firm received the Drugs Controller General of India’s (DCGI) nod for its COVID
Bharat Biotech to start Phase-1 trials for its second COVID-19 vaccine in Feb-March businessinsider.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.in Daily Mail and Mail on Sunday newspapers.
BBV154 (intranasal COVID-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India
Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for COVID-19 in Feb-March
India
Updated: Friday, January 8, 2021, 13:17 [IST]
Hyderabad, Jan 08: Buoyed by theEmergency Use Authorisation approval from theDrug Controller General of India (DCGI)for its COVID-19 vaccine Covaxin,Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.
Besides Covaxin, BharatBiotechhas been actively working on developing another vaccine, for which it tied up with Washington UniversitySchool of Medicine in St Louis for the novel chimp-adenovirus (Chimpanzee adenovirus), a single doseintranasalvaccine for COVID-19. BBV154 (intranasal COVID-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021, an email reply from the city-base